熊本大学エイズ学研究センター 教授
日本内科学会 認定内科医 日本癌学会 会員 日本血液学会 会員 日本免疫学会 会員
続きを読む
日本内科学会 | 認定内科医 |
---|---|
日本癌学会 | 会員 |
日本血液学会 | 会員 |
日本免疫学会 | 会員 |
熊本大学病院
1981年 熊本大学医学部卒業
1981年 熊本大学病院・日赤熊本病院にて臨床研修
1983年 熊本大学大学院医学研究科博士課程入学
1983年 アメリカ国立癌研究所臨床腫瘍部門研究員
(Samuel Broder教授のもとでレトロウイルス感染と免疫についての研究に従事)
1987年 熊本大学附属病院輸血部助手
1989年 熊本大学医学博士学位取得
1997年 熊本大学エイズ学研究センター病態制御分野(現:松下プロジェクト研究室)教授
【論文】
1 Alam M, Kuwata T, Shimura K, Yokoyama M, Ramirez Valdez KP, Tanaka K, Maruta Y, Oishi S, Fujii N, Sato H, Matsuoka M, Matsushita S. Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology. 13(1):70, 2016.
2 Kuwata T., Enomoto I., Baba M., Matsushita S. Incompatible natures of HIV-1 envelope in resistance to the CCR5 antagonist cenicriviroc and neutralizing antibodies. Antimicrobial Agents and Chemotherapy. 60:437-50, 2015
3 Matsushita, S., Yoshimura, K., Ramirez, K.P., Pisupati, J., Murakami, T. Passive transfer of neutralizing monoclonal antibody KD-247reduces plasma viral load in patients chronically infected with HIV-1. AIDS, 29: 453-462, 2015.
4 Ramírez K.P., Kuwata, T., Maruta Y, Tanaka K., Muntasir A., Yoshimura K., Matsushita S* Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 475:187-203, 2015.
5 Yoshimura, K., Harada, S., Boonchawalit, S., Kawanami, Y., and Matsushita, S.* Impact of maraviroc-resistant and low-CCR5- adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies. J. Gen. Virol., 95, 1816-1826, 2014.
6 Kuwata T., Takaki K., Yoshimura K., Enomoto I., Wu F., Ourmanov K.I., Hirsch V.M., Yokoyama M., Sato H. &Matsushita S.* Conformational Epitope Consisting of the V3 and V4 Loops as a Target for Potent and Broad Neutralization of Simian Immunodeficiency Viruses. J. Virol. 87:5424-5346 , 2013.
7 Harada S., Yoshimura K. *, Yamaguchi A., Yusa K. & Matsushita S. Impact of antiretroviral pressure on selection of primary HIV-1 envelope sequences in vitro. J. Gen. Virol. 94:933-943, 2013.
8 Kuwata T., Takaki K., Enomoto I., Kazuhisa Y. & Matsushita S.* Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Frontiers in Microbiology/Virology. 4:1-7 , 2013.
9 Yoshimura K., Harada, S., Shibata, J., Hatada M., Yamada Y., Ochiai C., Tamamura H. & Matsushita, S.* Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J. Virol. 84:7558-7568, 2010.
10 Hatada M., Yoshimura K., Harada S., Kawanami Y., Shibata J. & Matsushita S.* HIV-1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. J. Gen. Virol. 91: 1335-1345, 2010.
11 Shibata J., Yoshimura K., Honda A., Koito A., Murakami T. & Matsushita S.* Impact of V2 mutations for escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary HIV-1 isolate. J. Virol. 81,3757-3768, 2007.
12 Ikeda T., Shibata J., Yoshimura K., Koito A. & Matsushita S.* Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective HAART. J. Infect. Dis. 195:716-725, 2007.
13 Yoshimura K., Shibata J., Kimura T., Honda A., Maeda Y., Koito A., Murakami T., Mitsuya H. & Matsushita S.* Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favorable synergism with anti-CCR5 inhibitors. AIDS. 20: 2065-2073, 2006.
14 Matsushita S. *, Yoshimura, K., Kimura T., Kamihira, A., Takano, M., Eto, K., Shirasaka, T., Mitsuya, H. & Oka, S. Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir R containing regimen. J. Clin.Virol. 33:188-193, 2005.
15 Wang F.X., Kimura T., Nishihara K., Yoshimura K., Koito A. & Matsushita S.* Emergence of autologous neutralization-resistant variants from pre-existing quasispecies during viral-rebound of human immunodeficency virus type-1 infected patients under treatment of highly active antiretroviral therapy (HAART).J Infect Dis, 185:608-617, 2002.
16 Kimura T., Yoshimura K., Nishihara K., Maeda Y, Matsumi S., Koito A. Matsushita S.* Reconstitution of spontaneous neutralizing antibody response against autologous HIV-1 in chronically infected patients during highly active antiretroviral therapy. J. Infect. Dis., 185:53-60, 2002.
17 Matsushita S. *, Matsumi S., Yoshimura K., Morikita T., Murakami T. Takatsuki K.Neutralizing mooclonal antibodies against HIV-2 gp120. J. Virol. 69: 3333-3340, 1995.
18 Matsumi S., Matsushita S. *, Yoshimura K., Javaherian K. & Takatsuki K. Neutralizing monoclonal antibody against an external envelope glycoprotein (gp110) of SIVmac 251. AIDS Res. Hum. Retroviruses. 11: 501-508,1995.
19 Emini E.A. *, Schleif W. A., Nunberg J. H., Conley A.J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Fett C.M., Eichberg J.W. & Murthy K.K. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature, 355(20):728, 1992.
20 Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K. & Putney S.D. Characterization of human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:2107-2114, 1988 .
21 Matsushita S., Mitsuya H., Reitz M. & Broder S. Pharmacological inhibition of in vitro infectivity of human lymphotropic viurs type-I (HTLV-I). J. Clin. Invest. 80:394-400 1987.
22 Matsushita S., Robert-Guroff M., Trepel J., Cossman J., Mitsuya H. & Broder S. Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type-I. Proc. Natl. Acad. Sci. (USA) 83:3672-3676,1986.
23 Mitsuya H., Popovic M., Yarchoan R., Matsushita S., Gallo R.C. & Broder S. Suramin Protection of T-cells, in vitro against infectivity and cytopathic effects of HTLV-III. Science 226:172-174,1984.
【受賞】 1995年4月4日 第8回日本内科学会奨励賞受賞
本ページにおける情報は、医師本人の申告に基づいて掲載しております。内容については弊社においても可能な限り配慮しておりますが、最新の情報については公開情報等をご確認いただき、またご自身でお問い合わせいただきますようお願いします。
なお、弊社はいかなる場合にも、掲載された情報の誤り、不正確等にもとづく損害に対して責任を負わないものとします。